Pancreatic exocrine neoplasm

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …

This large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new daily pill, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific KRAS G12D gene mutation. Participants must have already tried at least one standard treatment. The goal is to see if the new drug helps peopl…

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This early-stage trial is testing whether adding an experimental cancer vaccine (ELI-002 7P) and an immunotherapy drug (tislelizumab) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with a specific type of pancreatic cancer that has a KRAS mutation. The st…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study explores whether growing miniature versions of a patient's own pancreatic tumor in the lab (called organoids) can help doctors choose the most effective drug for that individual. About 25 adults with advanced, inoperable pancreatic cancer will have their tumor organoid…

This study tests a new approach for locally advanced pancreatic cancer: tiny radioactive sources placed directly into the tumor to deliver alpha radiation. The treatment is combined with standard chemotherapy. The main goal is to check safety in 40 participants, but researchers w…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This phase III trial tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The study compares higher-dose radiation to standard care (more chemo, observat…

This early-stage trial tests whether injecting an immune-boosting drug (mitazalimab) directly into the tumor during a special electrical ablation procedure (IRE) is safe for people with locally advanced pancreatic cancer. The goal is to see if this approach can strengthen the bod…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This phase 3 trial tests whether adding setidegrasib (ASP3082) to standard chemotherapy helps people with a specific KRAS G12D mutation in metastatic pancreatic cancer live longer. About 614 adults will be randomly assigned to receive either setidegrasib or a placebo, along with …

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a three-drug chemotherapy regimen given at lower, continuous doses for people with metastatic pancreatic cancer. The drugs—capecitabine, oxaliplatin, and irinotecan—are dosed based on a patient's genetic profile to reduce side effects. The goal is to see if this …

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This phase 2 trial is testing whether giving two immunotherapy drugs, durvalumab and oleclumab, before surgery can boost the immune system's attack on pancreatic cancer. The study involves people with resectable pancreatic ductal adenocarcinoma (PDAC) who will receive the drugs i…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This trial compares two types of keyhole surgery to remove the tail of the pancreas. One uses a dye called indocyanine green that glows under special lights, helping surgeons see blood flow and decide where to cut. The other is the standard procedure without the dye. The goal is …

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests a combination of two drugs, pembrolizumab and olaparib, in people with advanced pancreatic cancer that has spread to other parts of the body. To join, participants must have tumors with high mutation levels or specific DNA repair problems. The goal is to see if t…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This study tests a new treatment called EGFR FPBMC for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer cells, then given back through an …

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. The goal is to see if it's safe and possible to place these tiny seeds in people with advanced pancreatic cancer that can't be removed by surgery. The study will enroll 15 par…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This early-phase trial tests an experimental drug called ES502 in people with advanced pancreatic cancer that has a specific genetic change (RAS G12V) and who have run out of standard treatments. ES502 is a lab-made protein designed to guide the body's immune T-cells to attack ca…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. It is for people with advanced pancreatic cancer that cannot be removed by surgery. The main goals are to see if the procedure is safe and possible to do. About 15 participant…

This study tests a new device called DaRT that delivers a special type of radiation directly into pancreatic tumors. It is being combined with standard chemotherapy in 30 people with advanced or metastatic pancreatic cancer. The main goal is to see if the combination is safe, and…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study tests a drug called M3814 combined with a special type of radiation for people with locally advanced pancreatic cancer (cancer that has spread nearby but not to distant organs). The goal is to find the safest dose and see if the combination helps stop tumor growth long…

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This early study tests a new catheter system that delivers the chemotherapy drug Gemcitabine directly into or near pancreatic tumors. It includes 9 patients with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach is safe and feasible…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…

This Phase 2 trial tests a combination of two immunotherapy drugs, odetiglucan and mitazalimab, as a maintenance treatment for people with unresectable pancreatic cancer that has not worsened after 4-8 months of standard chemotherapy. The study will enroll 100 adults and measure …

This early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Part…

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This Phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) and an immunotherapy drug (atezolizumab) to standard chemotherapy (mFOLFIRINOX) can keep pancreatic cancer from coming back after surgery. About 260 people whose tumors were completely remo…

This study tests a new combination of drugs for people with advanced pancreatic cancer that has spread or come back. The treatment includes an experimental antibody (BMS-986340) plus immunotherapy and two chemotherapy drugs. The goal is to see if this mix is safe and shrinks tumo…

This phase 2 trial tests whether giving a powerful chemotherapy regimen called NALIRIFOX along with targeted radiation and the drug capecitabine can shrink pancreatic tumors enough to allow successful surgery. The study enrolls 60 people with borderline resectable or locally adva…

This early-phase trial tests whether adding pegcetacoplan to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan targets part of the immune system to possibly slow tumor growth and reduce blood clots, a common comp…

This early-stage trial tests a new therapy that takes a patient's own immune T-cells, engineers them to recognize and attack pancreatic cancer cells with specific KRAS mutations, and infuses them back. The study includes 96 adults with advanced pancreatic cancer who have the righ…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy gemcitabine can help people with a certain genetic type of advanced pancreatic cancer live longer. The study enrolls 43 adults whose cancer has spread and who have already tried one…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-phase study tests a new gene therapy for people with pancreatic cancer that has returned after standard treatment. The therapy uses a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side eff…

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This phase 3 trial tests whether adding radiotherapy to standard chemotherapy after pancreatic cancer surgery can prevent the cancer from coming back. It enrolls 288 high-risk patients who have had surgery but still have factors like positive margins or lymph node involvement. Pa…

This study tests whether adding the drug BMS-986504 to standard chemotherapy can help control pancreatic cancer in people with a specific genetic change (MTAP deletion). About 60 adults with this type of pancreatic cancer will receive the combination before and after surgery or w…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This phase 2 trial is testing a new drug combination for people with advanced pancreatic cancer that has a specific mutation called KRAS G12D. The treatment combines HRS-4642 (a drug that targets the mutated protein), nimotuzumab (an antibody that blocks a growth signal), and sta…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This phase 2 study tests a new drug called IBI343 combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) in people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This early-phase trial tests a new way to deliver chemotherapy directly to the lining of the abdomen in people with pancreatic cancer that has spread there. The treatment, called PIPAC, uses a spray of chemotherapy drugs under pressure to reach tumor spots more effectively. The s…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This program offers a personalized vaccine called PCNAT-01 to patients with pancreatic cancer who have had surgery and finished chemotherapy. The vaccine is made from each patient's unique tumor proteins and is given as shots to train the immune system to fight any remaining canc…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests a procedure that uses a thin, flexible tube with a camera and ultrasound to guide a needle into pancreatic cysts. Chemotherapy drugs are injected directly into the cyst to shrink or destroy precancerous cells. The goal is to prevent these cysts from developing in…

This Phase 3 trial tests whether a new combination of drugs—TQB2868 (a dual antibody) plus anlotinib capsules—works better than standard chemotherapy for people with metastatic pancreatic cancer that has spread. About 566 participants will be randomly assigned to receive either t…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This early-phase trial tests an experimental drug called ASP2138 in 25 adults with resectable pancreatic cancer whose tumors have a specific protein (CLDN18.2). Participants receive ASP2138 two weeks before surgery, then standard chemotherapy after surgery. The main goal is to ch…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This trial tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults who have not had prior treatment for their advanced cancer will be randomly assigned to the new combo or …

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without …

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…

This phase 2 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy (gemcitabine and albumin-bound paclitaxel) can help shrink pancreatic tumors before surgery and prevent recurrence afterward. About 30 adults with resectable or borderline resecta…

This phase 2 trial is testing a combination of four drugs (HRS-4642, gemcitabine, albumin-bound paclitaxel, and adebrelimab) as treatment for pancreatic cancer before and after surgery. The goal is to see if this approach is safe and effective at shrinking tumors and improving su…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This study tests a new drug (HRS-4642) combined with an immunotherapy (adebrelimab) and possibly other cancer drugs for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to find safe doses and see if the combination can shrink tumor…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests a new way to deliver radiation directly into pancreatic tumors using tiny radioactive beads. It is for people with locally advanced pancreatic cancer that has not spread but cannot be removed by surgery. The goal is to see if this approach is safe and feasible, a…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study is for people with metastatic pancreatic cancer that has spread. It tests a new combination of three drugs (S-1, nab-paclitaxel, and gemcitabine) to find the safest and most effective dose. About 70 participants will take part to see how well the treatment shrinks tumo…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This study tests a new drug called DB-1324 in people with advanced or spreading stomach, bowel, or other gastrointestinal cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumor…

This early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…

This study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. About 56 adults with untreated pancreatic cancer will receive the combination. Th…

This early-stage trial tests an experimental drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 parti…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This phase II trial tests whether adding a precise, high-dose form of radiation (SBRT) to standard maintenance chemotherapy can help people with advanced pancreatic cancer live longer. The study enrolls 24 adults whose cancer has not grown after at least four months of initial ch…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This early-phase trial is testing an experimental drug called DA-3501 in 51 adults with advanced stomach, gastro-esophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). Participants receive the drug by IV once every three weeks. The main goals are to f…

This study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and …

This study is for people with metastatic pancreatic cancer that has worsened after initial treatment. It tests a new drug, ONT01, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) to see if it can reprogram immune cells in the tumor to fight cancer better. Abou…

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This phase 3 trial tests whether a multi-disciplinary treatment plan can help people with pancreatic cancer that has spread to only a few other places in the body live longer without the disease getting worse. About 80 adults with this condition will receive either standard care …

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This early-phase trial tests a combination of three drugs—regorafenib, toripalimab, and albumin-bound paclitaxel—as a third-line treatment for people with advanced pancreatic cancer that has spread or cannot be removed. The study aims to find the safest dose and see if the combo …

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …

This study tests whether adding all-trans retinoic acid to romiplostim N01 can better raise platelet counts in adults who have low platelets after finishing chemotherapy for gastrointestinal cancers. About 220 participants will receive either the combo or romiplostim alone for 12…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injecti…

This early-phase study tests whether tamoxifen, a drug commonly used for breast cancer, can shrink or stabilize pre-cancerous pancreatic cysts in women. The goal is to see if taking tamoxifen for up to 24 weeks can delay or eliminate the need for surgery. The study will enroll 15…

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This study tests a new drug (HRS-4642) combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in 30 people with locally advanced pancreatic cancer that has a specific gene change (KRAS G12D). The goal is to shrink tumors enough to allow surgery. Participants will ha…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…

This early-phase trial is testing a new drug, SKB500, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for ear…

This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This early-stage trial tests a new drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug every …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase trial is testing an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors. Part…

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

This study tests a new drug called SKB105 in 256 adults with advanced solid tumors that have not responded to standard treatments. SKB105 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial will first find the safest dose, then check…

This early-phase trial tests a new drug called SKB571 in 138 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. Participants recei…

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…

This program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…

This early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants w…

This early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an earl…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study compares two chemotherapy regimens for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. One group gets NALIRIFOX (a mix of four drugs) every two weeks, while the other gets a modified version of gemcitabine, nab-paclitaxel, and ci…

This study is testing a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with a precise type of radiation called proton therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the highest safe dose of…

This early-phase trial tests adding the cholesterol-lowering drug pitavastatin to standard chemotherapy (gemcitabine and nab-paclitaxel) as maintenance therapy for people with advanced pancreatic cancer that cannot be removed by surgery. About 18 adults whose disease is stable af…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and i…

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new drug called ODM-212 combined with other cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. A…

This study tests whether adding targeted radiation therapy (SBRT) to standard care helps people with pancreatic cancer that has returned only in the original area live longer and feel better. About 174 adults whose cancer came back locally after surgery will be randomly assigned …

This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dos…

This study tests a modified salmonella bacteria (SGN1) injected directly into tumors. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine), causing the tumors to shrink. The trial involves about 70 adults with advanced so…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The …

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study looks for new ways to diagnose pancreatic cancer, a disease that is often caught too late. Researchers will analyze fluid that is normally thrown away after a standard biopsy procedure. They hope to find proteins or other molecules that could lead to a simple blood tes…

This study compares two blood test methods for detecting circulating tumor cells (CTCs) that express a protein called Axl, which is linked to more aggressive cancer. The new technique, called EPIDROP, is being tested against the standard CellSearch method in patients with metasta…

This study is testing a new laser-based blood test that uses nanoparticles to detect pancreatic cancer early. Researchers will enroll 400 people, including those with diabetes, pancreatic cysts, or pancreatic cancer, to see if the test can accurately identify cancer. The goal is …

This study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…

This study tests whether a new ultrasound technique called SMI can accurately identify benign pancreatic cysts (serous cystadenomas). Currently, many patients with these harmless cysts undergo unnecessary surgery due to diagnostic uncertainty. The study will enroll 60 patients an…

This study tests whether a high-powered imaging technique called ultra-high resolution optical coherence tomography (OCT) can detect tiny, early-stage pancreatic cancers in tissue samples removed during surgery. Researchers will compare OCT images with standard lab analysis and a…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…

This study is testing a mixed meal test to better diagnose a specific type of diabetes (type 3c) that occurs in people with pancreatic cancer or chronic pancreatitis. Researchers will enroll 775 adults aged 30 to 84 who have new-onset diabetes and one of these pancreatic conditio…

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy …

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…

This study is testing a non-invasive breath test to detect pancreatic cancer earlier. Researchers will collect breath samples from over 6,000 people who have been referred for possible pancreatic cancer. The goal is to see if the test can accurately identify the small number of p…

This study aims to develop a non-invasive breath test to detect pancreatic cancer earlier. Pancreatic cancer is often diagnosed late because early symptoms are vague. The test measures tiny molecules in breath that may signal cancer. Researchers will collect breath and urine samp…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This pilot study tests whether a new, faster radiation planning method can safely ease severe abdominal pain caused by advanced cancer. Instead of a separate planning session, doctors use existing scans to create a treatment plan on the spot. Only 5 people will take part, and the…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. T…

This study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests whether a community health worker can help people newly diagnosed with pancreatic cancer feel better and manage their symptoms. The health worker meets with patients and their caregivers to address physical, emotional, and practical concerns, and helps coordinate…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study is testing an app called PancreasPlus for people with pancreatic cancer. The app helps patients track symptoms, get information, and communicate with their care team from home. Researchers want to see if using the app improves quality of life, reduces anxiety, and cuts…

This study tests four different approaches—behavioral therapy, physical therapy, medication changes, and buprenorphine rotation—to help cancer survivors reduce their opioid use while keeping pain under control. It involves 294 veterans who have finished cancer treatment but still…

This study tests a special medical food powder (Encala®) in 18 adults with pancreatic cancer who have trouble absorbing fat, causing stomach issues and weight loss. The goal is to see if the powder is easy to take and helps improve fat absorption and quality of life. This is an e…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study tests whether a remote exercise and nutrition program is practical and acceptable for people with pancreatic cancer who are waiting for surgery. Participants will use a Fitbit, get nutrition advice, and do resistance training at home. The goal is to see if this 'prehab…

This study tests whether giving a nerve block early, rather than waiting, can better control pain in people with inoperable pancreatic cancer. The procedure uses an endoscope to inject numbing medication near nerves that carry pain signals. Researchers will compare pain scores an…

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study tests whether playing a serious game on an iPad can help older adults (60+) better manage nausea and vomiting caused by chemotherapy. About 610 participants will be randomly assigned to play the game or receive usual care. Researchers will track symptom severity, quali…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…

This study is gathering health information from 2,000 adults with primary sclerosing cholangitis (PSC) to build a real-world data comparator group. The goal is to help design and run future drug trials more efficiently by providing a control group from real patient experiences. P…

This study is testing whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors pick the best drug for advanced cancers that have stopped responding to standard treatments. About 152 adults with colorectal or pancreatic cancer will have a biopsy to c…

This study looks at why people with pancreatic cancer often lose muscle and weight (cachexia). Researchers will collect blood, tissue, and imaging data from 500 patients to understand the biology and build an AI model that could warn doctors early. It is an observational study, s…

This study is tracking 20,000 people who have a family history of pancreatic cancer or carry genes that raise their risk. Researchers hope to find better ways to detect the disease early, when it's more treatable. Participants will be followed over time to see who develops pancre…

This study enrolls up to 15,000 children with known or suspected endocrine or metabolic disorders, along with their family members. Researchers will collect medical records, blood, saliva, and other samples to identify genetic changes linked to these conditions. The goal is to be…

This study is analyzing tissue and blood samples from 64 people with pancreatic cancer that has spread. Researchers want to understand how cancer cells change their energy use and interact with surrounding cells. The goal is to find new targets for treatment and better ways to pr…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study is testing a new technique called EXPEL to find biomarkers for pancreatic cancer. Researchers will analyze the fluid used to preserve biopsy samples from 200 patients with suspected pancreatic cancer. The goal is to identify proteins and other molecules that could help…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study compares two ways of monitoring pancreatic cysts—more frequent versus less frequent scans—and looks for biomarkers in the blood that might help predict cancer risk. About 770 adults aged 50 to 75 with at least one cyst will take part. The goal is to find out which moni…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well pancreatic cancer patients respond to chemotherapy. Researchers will track ctDNA levels before, during, and after treatment in 500 patients whose cancer has not spread. The goal …

This trial investigates whether a lidocaine infusion given during pancreatic cancer surgery can affect circulating tumor cells (CTCs) — cancer cells that may travel through the blood. Researchers will compare lidocaine to a saline placebo in patients undergoing robotic pancreatec…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study reviews medical records of 500 adults treated for benign or malignant pancreatic diseases since 2005. The goal is to understand how well different treatments worked over time. No new treatments are given—just careful analysis of past cases.

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at ways to increase genetic testing for people with breast, pancreatic, or colorectal cancer. Researchers will try different methods—like training doctors, giving feedback, and improving electronic health records—to see what helps oncology teams order more tests.…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This study explores whether a special MRI technique called 3D-MRE can measure the stiffness of pancreatic tumors to help predict how the disease will progress. Researchers will enroll 200 adults with pancreatic cancer and compare imaging results with actual tumor hardness and tre…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study aims to find pancreatic cancer earlier in people who are at higher-than-average risk due to family history or genetic mutations. Researchers will collect blood samples and health data from 30,000 participants over time to build a biobank. The goal is to improve early d…

This study tests whether a mobile app called MyCap can help track the time patients spend on pancreatic cancer treatment, including appointments, travel, and waiting. Thirty adults with pancreatic cancer who are on active treatment will use the app daily for 8 weeks. The goal is …

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study is creating a large database of 1,000 people with KRAS-mutant pancreatic cancer who are receiving targeted therapy. Researchers will track how long patients live and how long their cancer stays under control. The goal is to learn which treatments work best for differen…

This study looks at how obesity might help cause pancreatic cancer, especially in African American and non-Hispanic White people. Researchers will compare tumors and fat tissue from 125 adults to find differences that could lead to better treatments. The goal is to understand why…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study enrolls adults with known or suspected endocrine (hormone gland) disorders, such as diabetes or thyroid disease, to help researchers learn more about these conditions. Participants will undergo medical exams, blood and imaging tests, and possibly genetic testing. The m…

This study looks at how pancreatic cancer cells get and use nutrients to grow. Researchers will give a special sugar to 16 patients during surgery to trace the cancer's energy use in the lab. The goal is to find weaknesses in the cancer's fuel system that could lead to new treatm…

This study looks for three common BRCA gene mutations in 100 Ashkenazi Jewish people with pancreatic cancer. By understanding how often these mutations occur, researchers hope to improve early screening and prevention for at-risk family members. Participants provide a sample and …

This observational study tracks 80 people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Participants receive one of three treatment plans: a MEK inhibitor combined with other drugs, with or without hydroxychloroquine or an EGFR inhibitor. Th…

This pilot study aims to see if using five gene signatures from a patient's tumor can help doctors choose the best first chemotherapy for advanced pancreatic cancer. About 85 people with metastatic pancreatic cancer will have their tumor genes analyzed to pick between two standar…

This study tests whether personalized nutrition plans can improve recovery after Whipple surgery for pancreatic, bile duct, or ampullary cancers. Twenty patients in Pakistan will receive tailored meals and supplements before and after surgery, and be followed for 6 months. Resear…